Bio-Rad Laboratories, Inc. BIO.B Proceeds from exercises of stock options and other stock issuances
Proceeds from exercises of stock options and other stock issuances at other companies
Other financials
Where this comes from
Reported directly by Bio-Rad Laboratories, Inc. in its filing.
Tagged under the XBRL concept us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions.
The official record: Bio-Rad Laboratories, Inc.’s 10-K, filed February 13, 2026, on SEC EDGAR. View the filing →
Ask your AI about Bio-Rad Laboratories, Inc.'s proceeds from exercises of stock options and other stock issuances.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Bio-Rad Laboratories, Inc.'s proceeds from exercises of stock options and other stock issuances?
- Bio-Rad Laboratories, Inc. (BIO.B) reported proceeds from exercises of stock options and other stock issuances of $3.95M in Q4 2025.
- How has Bio-Rad Laboratories, Inc.'s proceeds from exercises of stock options and other stock issuances changed year-over-year?
- Bio-Rad Laboratories, Inc.'s proceeds from exercises of stock options and other stock issuances decreased by 17.7% year-over-year, from $4.8M to $3.95M.
- What is the long-term trend for Bio-Rad Laboratories, Inc.'s proceeds from exercises of stock options and other stock issuances?
- Over 4 years (2021 to 2025), Bio-Rad Laboratories, Inc.'s proceeds from exercises of stock options and other stock issuances has grown at a -6.5% compound annual growth rate (CAGR), from $20.63M to $15.8M.